Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment

doi:10.1111/bjd.19558

. 2021 Mar;184(3):548-550.

doi: 10.1111/bjd.19558. Epub 2020 Nov 10.

Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment

A Leutz¹, A Pinter², D Thaçi³, M Augustin⁴, C Schuster¹, K Fotiou¹, H P Hundemer¹, D Saure¹, U Mrowietz⁵, K Reich⁶

Affiliations

¹ Lilly Deutschland GmbH, Bad Homburg, Germany.
² University Clinic of Frankfurt am Main Department of Dermatology, Venereology and Allergology, Frankfurt am Main, Germany.
³ Institute and Comprehensive Center Inflammation Medicine, University zu Lübeck, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
⁴ Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
⁵ Psoriasis-Center, Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.
⁶ Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, and Skinflammation Center, Hamburg, Germany.

PMID: 32940343
DOI: 10.1111/bjd.19558

Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment

A Leutz et al. Br J Dermatol. 2021 Mar.

. 2021 Mar;184(3):548-550.

doi: 10.1111/bjd.19558. Epub 2020 Nov 10.

Authors

A Leutz¹, A Pinter², D Thaçi³, M Augustin⁴, C Schuster¹, K Fotiou¹, H P Hundemer¹, D Saure¹, U Mrowietz⁵, K Reich⁶

Affiliations

¹ Lilly Deutschland GmbH, Bad Homburg, Germany.
² University Clinic of Frankfurt am Main Department of Dermatology, Venereology and Allergology, Frankfurt am Main, Germany.
³ Institute and Comprehensive Center Inflammation Medicine, University zu Lübeck, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
⁴ Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
⁵ Psoriasis-Center, Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.
⁶ Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, and Skinflammation Center, Hamburg, Germany.

PMID: 32940343
DOI: 10.1111/bjd.19558

No abstract available

PubMed Disclaimer

Cited by

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Garcia-Doval I, Doney L, Dressler C, Hua C, Hughes C, Naldi L, Afach S, Le Cleach L. Sbidian E, et al. Cochrane Database Syst Rev. 2022 May 23;5(5):CD011535. doi: 10.1002/14651858.CD011535.pub5. Cochrane Database Syst Rev. 2022. Update in: Cochrane Database Syst Rev. 2023 Jul 12;7:CD011535. doi: 10.1002/14651858.CD011535.pub6 PMID: 35603936 Free PMC article. Updated. Review.
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Guelimi R, Garcia-Doval I, Hua C, Hughes C, Naldi L, Kinberger M, Afach S, Le Cleach L. Sbidian E, et al. Cochrane Database Syst Rev. 2023 Jul 12;7(7):CD011535. doi: 10.1002/14651858.CD011535.pub6. Cochrane Database Syst Rev. 2023. PMID: 37436070 Free PMC article. Review.
Using Automated Machine Learning to Predict Necessary Upcoming Therapy Changes in Patients With Psoriasis Vulgaris and Psoriatic Arthritis and Uncover New Influences on Disease Progression: Retrospective Study.
Schaffert D, Bibi I, Blauth M, Lull C, von Ahnen JA, Gross G, Schulze-Hagen T, Knitza J, Kuhn S, Benecke J, Schmieder A, Leipe J, Olsavszky V. Schaffert D, et al. JMIR Form Res. 2024 Jun 27;8:e55855. doi: 10.2196/55855. JMIR Form Res. 2024. PMID: 38738977 Free PMC article.

References

1. Mrowietz U, Kragballe K, Reich K et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303:1-10.
1. Wan MT, Alvarez J, Shin DB et al. Head-to-head trials of systemic psoriasis therapies: a systematic review of study design and maximum acceptable treatment differences. J Eur Acad Dermatol Venereol 2019; 33:42-55.
1. Reich K, Augustin M, Thaçi D et al. A 24-week multicentre, randomised, open-label, parallel-group study comparing the efficacy and safety of ixekizumab to fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment. Br J Dermatol 2020; 182:869-79.
1. Blauvelt A, Gooderham M, Iversen L et al. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). J Am Acad Dermatol 2017; 77:855-62.
1. Gordon KB, Blauvelt A, Papp KA et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 2016; 375:345-56.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

Grants and funding

NA/Eli Lilly and Company

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Mrowietz U, Kragballe K, Reich K et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303:1-10.

[2] Mrowietz U, Kragballe K, Reich K et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303:1-10.

[3] Wan MT, Alvarez J, Shin DB et al. Head-to-head trials of systemic psoriasis therapies: a systematic review of study design and maximum acceptable treatment differences. J Eur Acad Dermatol Venereol 2019; 33:42-55.

[4] Wan MT, Alvarez J, Shin DB et al. Head-to-head trials of systemic psoriasis therapies: a systematic review of study design and maximum acceptable treatment differences. J Eur Acad Dermatol Venereol 2019; 33:42-55.

[5] Reich K, Augustin M, Thaçi D et al. A 24-week multicentre, randomised, open-label, parallel-group study comparing the efficacy and safety of ixekizumab to fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment. Br J Dermatol 2020; 182:869-79.

[6] Reich K, Augustin M, Thaçi D et al. A 24-week multicentre, randomised, open-label, parallel-group study comparing the efficacy and safety of ixekizumab to fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment. Br J Dermatol 2020; 182:869-79.

[7] Blauvelt A, Gooderham M, Iversen L et al. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). J Am Acad Dermatol 2017; 77:855-62.

[8] Blauvelt A, Gooderham M, Iversen L et al. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). J Am Acad Dermatol 2017; 77:855-62.

[9] Gordon KB, Blauvelt A, Papp KA et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 2016; 375:345-56.

[10] Gordon KB, Blauvelt A, Papp KA et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 2016; 375:345-56.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment

Affiliations

Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment

Authors

Affiliations

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical